News & Videos - BIOLINERX LTD. ADS - Page 2

You are currently viewing all stock exchange news of the financial instrument BIOLINERX LTD. ADS regarding all markets in all languages.

> News PR Newswire published a news.

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer PR Newswire TEL AVIV, Israel, Sept. 19, 2023 Abstracts to be Published on American Association of Cancer Research (AACR) Virtual Meeting Platform at 5:30 pm EDT on Wednesday, September 27, 2023 Oral Presentation on Thursday, September 28, 2023 , in Boston , Massachusetts TEL AVIV, Israel , Sept. 19,...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma PR Newswire TEL AVIV, Israel, Sept. 11, 2023 - APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to achieve the collection goal...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates • • PR Newswire • Stocks

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, Aug. 30, 2023 - On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) - - Signed Exclusive License Agreement to Motixafortide in Asia Region with Concurrent Equity Investment - - Announced Initiation of Investigator-Initiated Randomized Phase 2 Combination...

Thank you Chart

> News PR Newswire published a news.

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 • • PR Newswire • Stocks

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 PR Newswire TEL AVIV, Israel, Aug. 22, 2023 - Management to Hold Conference Call at 10:00 a.m. EDT - TEL AVIV, Israel , Aug. 22, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, announced today it will release its unaudited financial results for the quarter ended June 30, 2023 on Wednesday, August 30,...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide PR Newswire TEL AVIV, Israel, July 17, 2023 TEL AVIV, Israel , July 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, today...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates • • PR Newswire • Stocks

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, May 24, 2023 On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and...

Thank you Chart

> News PR Newswire published a news.

BioLineRx to Report First Quarter 2023 Results on May 24, 2023 • • PR Newswire • Stocks

BioLineRx to Report First Quarter 2023 Results on May 24, 2023 PR Newswire TEL AVIV, Israel, May 17, 2023 Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel , May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its unaudited financial results for the quarter ended March 31, 2023 on Wednesday, May 24, 2023 , before the U.S. markets open. The Company...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement • • PR Newswire • Stocks

BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TEL AVIV, Israel, April 25, 2023 TEL AVIV, Israel , April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)....

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma PR Newswire TEL AVIV, Israel, April 17, 2023 - GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints - - Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates • • PR Newswire • Stocks

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, March 22, 2023 - Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M.D., as new Chief Medical Officer and Completed Formation of U.S. Commercial Leadership Team with Extensive Drug Launch and Sales Experience - -...

Thank you Chart

> News PR Newswire published a news.

BioLineRx to Report 2022 Annual Financial Results on March 22, 2023 • • PR Newswire • Stocks

BioLineRx to Report 2022 Annual Financial Results on March 22, 2023 PR Newswire TEL AVIV, Israel, March 15, 2023 Management to Hold Conference Call at 10:00 am EDT TEL AVIV, Israel , March 15, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it will release its audited financial results for the year ended December 31, 2022 on Wednesday, March 22, 2023 , before the U.S. markets open. The...

Thank you Chart

> News Business Wire published a news.

BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX • • Business Wire • Stocks

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”), of the important March 6, 2023 lead plaintiff deadline . SO WHAT: If you purchased BioLine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BioLine class...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease PR Newswire TEL AVIV, Israel, March 6, 2023 - Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas - TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage...

Thank you Chart

> News PR Newswire published a news.

BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX PR Newswire NEW YORK, March 4, 2023 NEW YORK , March 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022 , both dates inclusive (the "Class...

Thank you Chart

> News Business Wire published a news.

BIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm • • Business Wire • Stocks

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQ: BLRX) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired BioLineRx securities between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”). Investors have until...

Thank you Chart

> News PR Newswire published a news.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX • • PR Newswire • Stocks

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX PR Newswire NEW YORK, March 3, 2023 NEW YORK , March 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioLineRx Ltd. ("BioLineRx" or the "Company") (NASDAQ: BLRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether BioLineRx and certain of its officers and/or...

Thank you Chart

> News Business Wire published a news.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX) • • Business Wire • Stocks

The Law Offices of Frank R. Cruz reminds investors of the upcoming March 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQ: BLRX ) American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On September 15, 2022, BioLine announced that...

Thank you Chart

> News PR Newswire published a news.

BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit • • PR Newswire • Stocks

BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit PR Newswire LOS ANGELES, March 2, 2023 LOS ANGELES , March 2, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioLineRx Ltd. ("BioLine" or the "Company") (NASDAQ: BLRX ). Class Period: February 23, 2021 – September 19, 2022 Lead Plaintiff Deadline: March 6, 2023 If you are a shareholder...

Thank you Chart

> News PR Newswire published a news.

BLRX IMPORTANT DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX PR Newswire NEW YORK, Feb. 25, 2023 NEW YORK , Feb. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022 , both dates inclusive...

Thank you Chart

> News PR Newswire published a news.

BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit • • PR Newswire • Stocks

BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit PR Newswire BENSALEM, Pa., Feb. 23, 2023 BENSALEM, Pa. , Feb. 23, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioLineRx Ltd. ("BioLine" or the "Company") (NASDAQ: BLRX ). Class Period: February 23, 2021 – September 19, 2022 Lead Plaintiff Deadline: March 6, 2023 Investors suffering...

Thank you Chart